BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 24345274)

  • 1. BRAF-mutated pleomorphic xanthoastrocytoma is associated with temporal location, reticulin fiber deposition and CD34 expression.
    Koelsche C; Sahm F; Wöhrer A; Jeibmann A; Schittenhelm J; Kohlhof P; Preusser M; Romeike B; Dohmen-Scheufler H; Hartmann C; Mittelbronn M; Becker A; von Deimling A; Capper D
    Brain Pathol; 2014 Apr; 24(3):221-9. PubMed ID: 24345274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF V600E mutations are frequent in dysembryoplastic neuroepithelial tumors and subependymal giant cell astrocytomas.
    Lee D; Cho YH; Kang SY; Yoon N; Sung CO; Suh YL
    J Surg Oncol; 2015 Mar; 111(3):359-64. PubMed ID: 25346165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological and genetic association between epithelioid glioblastoma and pleomorphic xanthoastrocytoma.
    Furuta T; Miyoshi H; Komaki S; Arakawa F; Morioka M; Ohshima K; Nakada M; Sugita Y
    Neuropathology; 2018 Jun; 38(3):218-227. PubMed ID: 29532523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic alterations commonly found in diffusely infiltrating cerebral gliomas are rare or absent in pleomorphic xanthoastrocytomas.
    Kaulich K; Blaschke B; Nümann A; von Deimling A; Wiestler OD; Weber RG; Reifenberger G
    J Neuropathol Exp Neurol; 2002 Dec; 61(12):1092-9. PubMed ID: 12484572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The genetic landscape of anaplastic pleomorphic xanthoastrocytoma.
    Phillips JJ; Gong H; Chen K; Joseph NM; van Ziffle J; Bastian BC; Grenert JP; Kline CN; Mueller S; Banerjee A; Nicolaides T; Gupta N; Berger MS; Lee HS; Pekmezci M; Tihan T; Bollen AW; Perry A; Shieh JTC; Solomon DA
    Brain Pathol; 2019 Jan; 29(1):85-96. PubMed ID: 30051528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression.
    Chappé C; Padovani L; Scavarda D; Forest F; Nanni-Metellus I; Loundou A; Mercurio S; Fina F; Lena G; Colin C; Figarella-Branger D
    Brain Pathol; 2013 Sep; 23(5):574-83. PubMed ID: 23442159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of EZH2 expression, BRAF V600E mutation, and CDKN2A/B deletions in epithelioid glioblastoma and anaplastic pleomorphic xanthoastrocytoma.
    Wang J; Liu Z; Cui Y; Liu Y; Fang J; Xu L; He Y; Du J; Su Y; Zou W; Xu Z; Li G
    J Neurooncol; 2019 Aug; 144(1):137-146. PubMed ID: 31214915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. pRB immunostaining in the differential diagnosis between pleomorphic xanthoastrocytoma and glioblastoma with giant cells.
    Barresi V; Simbolo M; Ciaparrone C; Pedron S; Mafficini A; Scarpa A
    Histopathology; 2022 Nov; 81(5):661-669. PubMed ID: 35945679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Next-Generation Sequencing Reveals Divergent Clonal Evolution in Components of Composite Pleomorphic Xanthoastrocytoma-Ganglioglioma.
    Lucas CG; Davidson CJ; Alashari M; Putnam AR; Whipple NS; Bruggers CS; Mendez JS; Cheshier SH; Walker JB; Ramani B; Cadwell CR; Sullivan DV; Lu R; Mirchia K; Van Ziffle J; Devine P; Goldschmidt E; Hervey-Jumper SL; Gupta N; Oberheim Bush NA; Raleigh DR; Bollen A; Tihan T; Pekmezci M; Solomon DA; Phillips JJ; Perry A
    J Neuropathol Exp Neurol; 2022 Jul; 81(8):650-657. PubMed ID: 35703914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological characteristics of circumscribed high-grade astrocytomas with an unusual combination of BRAF V600E, ATRX, and CDKN2A/B alternations.
    Murakami C; Yoshida Y; Yamazaki T; Yamazaki A; Nakata S; Hokama Y; Ishiuchi S; Akimoto J; Shishido-Hara Y; Yoshimoto Y; Matsumura N; Nobusawa S; Ikota H; Yokoo H
    Brain Tumor Pathol; 2019 Jul; 36(3):103-111. PubMed ID: 30972500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications.
    Dias-Santagata D; Lam Q; Vernovsky K; Vena N; Lennerz JK; Borger DR; Batchelor TT; Ligon KL; Iafrate AJ; Ligon AH; Louis DN; Santagata S
    PLoS One; 2011 Mar; 6(3):e17948. PubMed ID: 21479234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Giant cell glioblastoma and pleomorphic xanthoastrocytoma show different immunohistochemical profiles for neuronal antigens and p53 but share reactivity for class III beta-tubulin.
    Martinez-Diaz H; Kleinschmidt-DeMasters BK; Powell SZ; Yachnis AT
    Arch Pathol Lab Med; 2003 Sep; 127(9):1187-91. PubMed ID: 12946225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF mutation and anaplasia may be predictive factors of progression-free survival in adult pleomorphic xanthoastrocytoma.
    Tabouret E; Bequet C; Denicolaï E; Barrié M; Nanni I; Metellus P; Dufour H; Chinot O; Figarella-Branger D
    Eur J Surg Oncol; 2015 Dec; 41(12):1685-90. PubMed ID: 26454767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MGMT Promoter Methylation and BRAF V600E Mutations Are Helpful Markers to Discriminate Pleomorphic Xanthoastrocytoma from Giant Cell Glioblastoma.
    Lohkamp LN; Schinz M; Gehlhaar C; Guse K; Thomale UW; Vajkoczy P; Heppner FL; Koch A
    PLoS One; 2016; 11(6):e0156422. PubMed ID: 27253461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of the CD34 antigen in pleomorphic xanthoastrocytomas.
    Reifenberger G; Kaulich K; Wiestler OD; Blümcke I
    Acta Neuropathol; 2003 Apr; 105(4):358-64. PubMed ID: 12624789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma.
    Schindler G; Capper D; Meyer J; Janzarik W; Omran H; Herold-Mende C; Schmieder K; Wesseling P; Mawrin C; Hasselblatt M; Louis DN; Korshunov A; Pfister S; Hartmann C; Paulus W; Reifenberger G; von Deimling A
    Acta Neuropathol; 2011 Mar; 121(3):397-405. PubMed ID: 21274720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions are frequent in epithelioid glioblastomas: a histological and molecular analysis focusing on intratumoral heterogeneity.
    Nakajima N; Nobusawa S; Nakata S; Nakada M; Yamazaki T; Matsumura N; Harada K; Matsuda H; Funata N; Nagai S; Nakamura H; Sasaki A; Akimoto J; Hirato J; Yokoo H
    Brain Pathol; 2018 Sep; 28(5):663-673. PubMed ID: 29105198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation.
    Vaubel RA; Caron AA; Yamada S; Decker PA; Eckel Passow JE; Rodriguez FJ; Nageswara Rao AA; Lachance D; Parney I; Jenkins R; Giannini C
    Brain Pathol; 2018 Mar; 28(2):172-182. PubMed ID: 28181325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additional genetic alterations in BRAF-mutant gliomas correlate with histologic diagnoses.
    Dono A; Vu J; Anapolsky M; Hines G; Takayasu T; Yan Y; Tandon N; Zhu JJ; Bhattacharjee MB; Esquenazi Y; Ballester LY
    J Neurooncol; 2020 Sep; 149(3):463-472. PubMed ID: 33009979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pleomorphic xanthoastrocytoma, anaplastic pleomorphic xanthoastrocytoma, and epithelioid glioblastoma: Case series with clinical characteristics, molecular features and progression relationship.
    Lin Z; Yang R; Zheng H; Li Z; Yi G; Wu Q; Yang C; Huang G
    Clin Neurol Neurosurg; 2022 Oct; 221():107379. PubMed ID: 35932588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.